Introduction. In clinical gene therapy trials, vectors derived from onco-retroviruses similar to the amphotropic murine leukemia virus (MLV-A) have often been used. However, MLV-derived vectors require active proliferation of the target cells for efficient transduction. Growth-arrested or slowly dividing cells are only poorly transduced. In contrast, vectors derived from lentiviruses are capable of transducing nonproliferating cells (1) and may thus be a useful alternative. Lentiviral vectors are generated by triple transfection into mammalian cells of plasmids harbouring the packaging (psi)-signal positive transfer vector gene as well as the psi-negative lentiviral gag/pol gene and a suitable psi-negative envelope gene construct. For efficient transduction of human cells, the G-protein of vesicular stomatitis virus (VSV-G) or the MLV-derived envelope glycoproteins (Env) can be used to generate pseudotype vector particles with a broad cell tropism (2) . Most often, human immunodeficiency virus type 1 (HIV-1) has been used to derive lentiviral vectors.
As an alternative to the use of HIV-1-derived vectors, other members of the lentivirus family have been used to derive vectors, e.g., HIV-2 (3), simian immunodeficiency virus (SIVmac) from rhesus macaques (Macaca mulatta; Ref. 4, 5) , or other nonprimate lentiviruses (6) . We report here the generation of a lentivirus vector derived from the molecular clone SIVagm3mc of simian immunodeficiency virus (SIVagm) from African green monkeys (AGMs; Cercocebus pygerythrus). Following natural infection as well as experimental inoculation, SIVagm has been shown to be apathogenic in AGMs and in pig-tailed macaques (Macaca nemestrina; Refs. 7, 8, [9] [10] [11] [12] [13] . In addition, SIVagm belongs to a phylogenetically distinct group of lentiviruses, which is very different from the HIV-2/SIVsm/SIVmac or the HIV-1/SIVcpz group of lentiviruses. Therefore, we used the apathogenic molecular virus clone SIVagm3mc to derive a new lentiviral vector system.
Results and Discussion. SIVagm vectors can be pseudotyped with VSV-G and packaged into HIV-1 vector particles.
First we tested the ability of the SIVagm-derived packaging construct S11b and the transfer vector S19-lacZ ( Fig. 1) to generate infectious vector particles upon cotransfection with the VSV-G envelope construct MD-G (14, 15) into 293T cells. As positive controls, HIV-1-and MLV-derived vectors pseudotyped with VSV-G were produced accordingly. 293T cells transfected with the packaging and transfer vector construct only, but not with an envelope-encoding plasmid, served as negative con-trols. Furthermore, the capability of SIVagm-and HIV-1-derived packaging constructs to cross-package the respective heterologous vector genome RNA was tested by transfection of the SIVagm-derived transfer vector construct with the HIV-1-derived packaging construct, and vice versa. Vectors were generated as described and titrated in human 293 kidney cells and D17 canine osteosarcoma cells (Table 1) . As shown, infectious SIVagm-derived vectors pseudotyped with VSV-G were efficiently produced upon triple cotransfection of respective plasmids and vector titers of 4 ϫ 10 4 IU/ml or more were measured in either one of the target cells. Transfer of the SIVagm-derived packaging construct S11b into target cells exposed to SIVagm-derived vector particles was not observed, as tested by immunostaining of the respective targeting cells using an anti-serum of a SIVagm-infected pig-tailed macaque able to detect SIVagm-Gag (Nem 170). This indicated that the deletion in the psi-site was sufficient to avoid copackaging into vector particles (data not shown). Absence of replication- (Table 1) . Whereas the packaging of HIV-1-transfer vectors into SIVagm core particles seemed to be inefficient, resulting in low vector titers, encapsidation of SIVagm3-derived vector genomes by HIV-1 core particles led to high-titer vector preparations, indicating efficient cross-packaging. This capability of vector components derived from SIVagm and HIV-1 to allow formation of RNA pseudotypes is consistent with the observed cross-packaging between SIVmac and HIV-1 (4). The use of HIV-1-derived packaging constructs and transfer vectors derived from apathogenic SIVagm3mc may prove suitable for the generation of lentiviral vectors with potentially increased safety in humans, since the sequence homology between these two vector components is further minimised and makes recombination and generation of replication competent lentiviruses less likely. In addition, it is feasible to assume that cross-packaging of SIVagmderived vector genomes will lead to a further enhanced inhibitory effect on HIV replication due to a TAR and RRE decoy effect when used to transduce HIV-1-infected cells (16) . Therefore, this novel vector system may especially contribute to future gene therapy strategies against HIV-1 infection and AIDS.
SIVagm3 Vectors Efficiently Transduce GrowthArrested Cells.
To test the capability of the SIVagm3mc-derived vectors to transduce growth-arrested cells, transduction experiments were performed using proliferating and growth-arrested human target cells in parallel. Vector stocks were therefore generated as described and titrated in 293 cells. To achieve comparable transduction efficacies, vector stocks were adjusted to 1 ϫ 10 5 IU/ml and again titrated in human 293 kidney cells using serial dilutions. Growth arrest of target cells was achieved by seeding cells 24 h prior to infection in standard culture media containing 20 g/ml of the DNA polymerase inhibitor aphidicolin. Growth arrest in G 1 /S of more than 97% of the cells was confirmed by FACS analysis after propidium iodide staining as described elsewhere (data not shown; Ref. 17) . Two days posttransduction, LacZ-positive cells were visualised by X-Gal staining ( Table 2) . As expected, MLV-derived vectors were not capable of transducing aphidicolin-treated cells. In contrast, SIVagm-and HIV-1-derived vector particles mediated gene transfer into growth-arrested cells with comparable efficiencies. Obtained transduction efficiencies in growth-arrested cells ranged between 20 and 40% for the SIVagm-derived vectors and 40 and 80% for the HIV-1-based vector particles, compared to the respective titers in proliferating target cells. These results clearly demonstrate the ability of vector particles derived from apathogenic SIVagm3mc to enable the transduction of growth-arrested human cells. This property is believed to be crucial for successful gene delivery in vivo in future gene therapy applications (15) .
SIVagm Vectors are Capable of Transduction of Neuronal and Glial Cells In Vivo.
Adult female Fischer 344 rats (n ϭ 5, injection sites n ϭ 10) were anesthesised (44 mg/kg ketamine, 0.75 mg/kg acepromazine, 4mg/kg xylazine, in 0.9% NaCl ip) and 3 l of an [SIVagm(VSV-G)] vector preparation generated by cotransfection of 293T cells with pS11b, pS19-lacZ, and pMD-G followed by concentration via ultracentrifugation to 3 ϫ 10 6 IU/ml was injected into the striatum (AP ϩ 0.2, ML Ϯ 3.5, DV Ϫ 4.5) bilaterally using a 5-l Hamilton syringe (15, 18, 19) . After 4 weeks, animals were sacrificed and analysed for ␤-Gal-positive cells in the striatum (Fig. 2) . All adult rat brain injection sites showed expression of the transgene. No inflammatory reaction was noticed. Immunofluorescent staining with a rabbit polyclonal antibody against ␤-Gal revealed transduction of different cell types of the central nervous system. Counterstaining for cell-specific markers, such as NeuN for terminally differentiated neurons, GFAP for astrocytes, and Rip for oligodendrocytes, showed that the vectors transduced neu- cells of HIV-1 may be achievable. Major drawbacks of these vectors may be the expected fast neutralisation by HIV-1-specific antibodies in HIV-1-infected patients and the very likely further decreased vector titer when genes are transferred that inhibit the replication of HIV-1, such as ribozymes, RNA decoys, and single-chain antibodies (scFv) directed against conserved HIV-1 sequences or epitopes, respectively. Assuming that these inhibitory genes interfere with the viral vector components, it is very likely that this will have a negative impact on vector titers. As SIVagm is only poorly neutralised by sera from HIV-1-infected patients (22) and is only distantly related to HIV-1, such inhibitory effects are not expected using SIVagm-derived vector particles displaying the homologous envelope glycoproteins. We therefore wanted to test the possibility of generating SIVagm-derived vectors displaying their natural CD4-dependent tropism. Thus, 293T cells were cotransfected with the packaging construct S11b, the plasmid pS19-lacZ harbouring the transfer vector, and the envelope construct Rep ⌬10 env (Fig.  1 ) encoding a C-terminally truncated variant of the transmembrane protein and the full-length surface envelope glycoprotein of SIVagm3mc (22) ϩ /CXCR4 ϩ U87 cells was higher than expected. However, it was assumed that this may have resulted from a background of Bonzo expression in U87 cells. In summary, these observations showed that selective gene transfer into human CD4 ϩ /CCR5 ϩ cells is achieved using [SIV(SIV)] vectors carrying the envelope glycoproteins of SIVagm3mc. To exclude rapid generation of replication-competent virus during vector preparation, an assay similar to that described above was performed. Following transduction of C8166 T cells with each of the vectors listed in Table 3 and subsequent cultivation of the respective cells for another 4 weeks, no RT activity was detected (data not shown). Thus, using such envelope mutants, these vectors derived from apathogenic SIVagm3mc should be able to circumvent the major drawbacks of HIV-1-based vectors.
Materials and Methods. Vector components. Expression constructs used for the generation of vectors are shown in Fig. 1 . Details of the construction are available from the authors upon request. Briefly, the packaging construct S11b encompasses the functional genes gag/ pol, vif, vpx, tat, and rev. The env gene was truncated to a final extent of only 1035 nt of originally 2631 nt by inserting a stop codon at nt position 6809. The putative packaging signal psi (⌿) was removed by deleting a 19-nt fragment (nt 334-353). The 5ЈLTR was replaced by a CMV promoter, whereas the 3ЈLTR was substituted by the polyadenylation signal [p(A)] of the bovine growth hormone gene (BGH). The transfer vector S19-lacZ contains the flanking LTRs of SIVagm3mc, the rev-responsive element (RRE), and the splice donor (SD) and acceptor (SA) of SIVagm3mc, as indicated. The first 1559 nt of the gag gene were included but transcription was abrogated by deleting the start codon. The lacZ reporter gene is driven by a CMV promoter. The envelope construct pMD-G was used to pseudotype all vector particles described here with VSV-G. The envelope constructs pTr712 and pRepSIVagm⌬10env have been previously described (22) and encompass truncated variants of the envelope genes derived from T-cell tropic HIV-1 and SIVagm3mc driven by the human ␤-actin promoter and the 3ЈLTR of Rous sarcoma virus (RSV), respectively.
Generation of Vector Particles and Infection of Target
Cells. SIVagm3-derived constructs were designed to allow generation of the vectors by cotransfection of three plasmids into 293T cells. The transfer vector harbouring the reporter gene lacZ, the packaging construct encompassing the lentiviral genes (gag/pol, vif, vpx, tat, and rev), and the VSV-G encoding gene were located on three separate plasmids (Fig. 1) 5 293T cells using the reagent Lipofectamin P (Gibco, Eggenstein, Germany) according to the manufacturer's instructions. Forty-eight hours posttransfection cell culture supernatants were freed from contaminating cells by passaging through a 0.45-m filter and subsequently used in various dilutions to infect 2 ϫ 10 5 target cells in a total volume of 1 ml. After 2 h of coincubation of cells and vector particles, target cells were washed and expanded. All cells were cultured using DMEM (Gibco) supplemented with 10% fetal calf serum (FCS, Seromed, Berlin, Germany). Determination of vector titers was performed by X-Gal assay and counting of ␤-Gal-positive cells.
Analysis of Rat Brains for
Expression of ␤-Galactosidase. Animals were perfused intracardially with saline, 4% paraformaldehyde, and 0.2% glutaraldehyde. The brains were removed, postfixed, and saturated in 30% sucrose. Brains were frozen sectioned on a sliding microtome into 50-m slices. Primary antibodies (Ab) used for immunohistochemistry were incubated overnight at 4°C in the following dilution: rabbit AB against ␤-galactosidase (Cortex, 1:10,000), mouse Ab against NeuN detecting terminally differentiated neurons (Chemi-Con, 1:500), guinea pig Ab (Advanced Immunochemicals, 1:250), or mouse Ab against GFAP (Chemi-Con, 1:1000) detecting astrocytes and mouse Ab against Rip-detecting oligodendrocytes (Chemi-Con, 1:20,000). Corresponding fluorescent-coupled secondary antibodies (Cy3, FITC, Jackson, 1:250) were used and nuclear staining was achieved by diamidino-2-phenylindole (Molecular Probes). The sections were analysed by confocal scanning laser microscopy (Leica). The signals were collected, digitally colour enhanced, and superimposed with Photoshop 5.0 (Adobe Photoshop).
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